Yahoo Finance

Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease (CAD) offers more accurate non-invasive diagnosis, fewer unnecessary tests, and higher confidence in identifying patients needing treatment

Precision Pathway compared to Traditional Testing for stable chest pain and suspected coronary artery disease.

MOUNTAIN VIEW, Calif., Nov. 06, 2022 (GLOBE NEWSWIRE) -- Please note the link in the second paragraph has been updated from the original release issued under the same headline earlier today by HeartFlow Holding, Inc. The corrected release follows:

HeartFlow, Inc., the leader in revolutionizing precision heartcare, today announced new trial results that show evaluating patients with suspected CAD by applying advanced artificial intelligence (AI) to CCTA allows for more accurate non-invasive diagnosis, reduces unnecessary testing, and offers higher confidence in identifying patients needing treatment.

The results from the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) trial were presented today as late-breaking clinical data at the American Heart Association’s (AHA) Scientific Sessions in Chicago, IL.

“This is the strongest level of scientific evidence yet to support the approach professional guidelines recommend that physicians use to diagnose stable chest pain patients,” said Pamela Douglas, M.D., MACC, FASE, FAHA, the Ursula Geller Professor for Research in Cardiovascular Disease, Duke University School of Medicine and study chair of the PRECISE trial. “Combining multiple steps into a Precision Pathway provides a clear path forward for clinicians.”

PRECISE is the first global randomized controlled trial of its kind, enrolling 2,103 participants at 65 sites. The trial confirms that the CCTA ± FFR_CT-centered strategy, recognized by the AHA/ACC Guidelines, is the superior diagnostic pathway for patients with suspected coronary artery disease.

The trial compares a non-invasive Precision Pathway to Traditional Testing which includes stress testing or invasive cardiac catheterization. The Precision Pathway is consistent with the AHA/ACC guideline-recognized approach that defers testing for low-risk patients and tests all others with CCTA ± FFR_CT. The FFR_CT Analysis uses AI coupled with highly trained analysts to create an interactive 3D computer model of the heart that quantifies and displays blood flow and blockages.

Compared to Traditional Testing, the PRECISE trial showed that the Precision Pathway:

1. allows for more accurate non-invasive diagnosis, significantly lowering the rates of false negatives and false positives compared to Traditional Testing in patients with coronary artery disease.

2. reduces unnecessary tests, providing a better patient experience, with a 4x reduction in unnecessary invasive catheterization and necessitating fewer initial diagnostic tests overall.

3. provides confidence in treating the right patients - 75% more likely to identify patients in need of intervention.